Form 4: Oncology Institute CEO Acquires Shares and Warrants in Private Placement

Daniel Virnich, CEO of Oncology Institute, purchased shares and warrants in a private placement, increasing his holdings in the company.

Summary

• Daniel Virnich, the CEO of Oncology Institute, acquired 22,640 shares of common stock at $1.0417 per share and 11,320 common warrants at $0.1250 per warrant on March 26, 2025.
• These securities were purchased through a private placement transaction directly from the company.
• The private placement involved units consisting of two shares of common stock and one common warrant, priced at $2.2084 per unit.
• Following the transaction, Virnich directly owns 724,363 shares of common stock and 11,320 common warrants.
• The issuance of these securities was approved by the company's board of directors and deemed exempt under Rule 16b-3 of the Securities Exchange Act of 1934.
• Virnich is restricted from exercising the warrants if it would result in him owning more than 9.99% of the company's outstanding common stock.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The CEO's investment in the company through a private placement suggests confidence in the company's future, but it's a routine transaction.

Positives

• The CEO's participation in the private placement could be seen as a positive signal, indicating confidence in the company's future prospects.
• The private placement provides the company with additional capital.

Risks

• The restriction on warrant exercise to maintain ownership below 9.99% could limit the CEO's ability to fully capitalize on the warrants if the stock price increases significantly.

Future Outlook

The document does not contain specific forward-looking statements, but the CEO's investment suggests a positive outlook.

Industry Context

Insider transactions are common in the healthcare industry, and this purchase is typical of executives increasing their stake in their own companies. It's important to monitor how these transactions correlate with the company's performance and strategic initiatives.

Comparison to Industry Standards

• Comparing this transaction to similar insider purchases in comparable oncology-focused companies would provide a benchmark.
• For example, if executives at companies like Exact Sciences or Guardant Health have recently made similar purchases, it could indicate a broader trend of confidence in the sector.
• The size of the purchase relative to Virnich's existing holdings and the company's market capitalization is also relevant for comparison.

Stakeholder Impact

• Shareholders may view the CEO's purchase positively, potentially increasing investor confidence.
• The capital raised through the private placement could benefit the company's operations and growth, indirectly impacting employees and other stakeholders.

Key Dates

Keywords

private placement, common stock, common warrant, Oncology Institute, TOI, Daniel Virnich, CEO, acquisition, Rule 16b-3, beneficial ownership